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Fosfomycin and Tobramycin in Combination Downregulate Nitrate
Reductase Genes narG and narH, Resulting in Increased Activity
against Pseudomonas aeruginosa under Anaerobic Conditions
Gerard McCaughey,a,b Deirdre F. Gilpin,a,b Thamarai Schneiders,c Lucas R. Hoffman,d Matt McKevitt,e J. Stuart Elborn,a,c
Michael M. Tunneya,b
CF and Airways Microbiology Research Group, Queen’s University, Belfast, United Kingdoma; School of Pharmacy, Queen’s University, Belfast, United Kingdomb; Centre for
Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, United Kingdomc; Department of Pediatrics, University of
Washington School of Medicine, Seattle, Washington, USAd; Gilead Sciences, Inc., Seattle, Washington, USAe
The activity of aminoglycosides, which are used to treat Pseudomonas aeruginosa respiratory infection in cystic fibrosis (CF)
patients, is reduced under the anaerobic conditions that reflect the CF lung in vivo. In contrast, a 4:1 (wt/wt) combination of
fosfomycin and tobramycin (F:T), which is under investigation for use in the treatment of CF lung infection, has increased activ-
ity against P. aeruginosa under anaerobic conditions. The aim of this study was to elucidate the mechanisms underlying the in-
creased activity of F:T under anaerobic conditions. Microarray analysis was used to identify the transcriptional basis of increased
F:T activity under anaerobic conditions, and key findings were confirmed bymicrobiological tests, including nitrate utilization
assays, growth curves, and susceptibility testing. Notably, growth in subinhibitory concentrations of F:T, but not tobramycin or
fosfomycin alone, significantly downregulated (P< 0.05) nitrate reductase genes narG and narH, which are essential for normal
anaerobic growth of P. aeruginosa. Under anaerobic conditions, F:T significantly decreased (P< 0.001) nitrate utilization in P.
aeruginosa strains PAO1, PA14, and PA14 lasR::Gm, a mutant known to exhibit increased nitrate utilization. A similar effect was
observed with two clinical P. aeruginosa isolates. Growth curves indicate that nitrate reductase transposon mutants had reduced
growth under anaerobic conditions, with these mutants also having increased susceptibility to F:T compared to the wild type
under similar conditions. The results of this study suggest that downregulation of nitrate reductase genes resulting in reduced
nitrate utilization is the mechanism underlying the increased activity of F:T under anaerobic conditions.
The lungs of cystic fibrosis (CF) patients contain aerobic, mi-croaerophilic, and anoxic regions, with pathogens such as
Pseudomonas aeruginosa and strict anaerobic bacterial species
growing in diverse polymicrobial communities within these
niches (1, 2). P. aeruginosa, which is regarded as the principal
causative pathogen of respiratory infection in CF patients (3), is
well adapted to proliferate under anaerobic conditions by the use
of nitrate as the terminal electron acceptor in respiration (4). Ni-
trate is present in CF sputum at sufficient levels (average of ap-
proximately 400 M) to support the anaerobic growth of P.
aeruginosa (5). Moreover, anaerobiosis is known to affect the ac-
tivity of some classes of antimicrobials, with previous studies
showing that tobramycin, amikacin, aztreonam, colistin, and cip-
rofloxacin have reduced bactericidal activity against P. aeruginosa
under these conditions (6–8).
P. aeruginosa has the ability to become rapidly multiply antibi-
otic resistant, via either the acquisition of resistance elements or
mutation; current reports show that it is becoming progressively
more resistant to many currently available antimicrobials (9–11).
Therefore, there is a need for new agents with activity against this
pathogen, and it would be particularly beneficial if such agents
were active under anaerobic conditions.
A 4:1 (wt/wt) combination of fosfomycin and tobramycin
(F:T) is under investigation as a potential inhalation therapy
for use in CF patients. We have previously shown that F:T or
fosfomycin alone has good in vitro activity against P. aeruginosa
and, importantly, increased activity under anaerobic condi-
tions, reflecting the CF lung environment in vivo (12). In addi-
tion, we have shown that F:T was bactericidal against P. aerugi-
nosa grown in biofilms under both aerobic and anaerobic
conditions (12).
We hypothesized that the increased activity of F:T under an-
aerobic conditionsmay bemediated through either fosfomycin or
tobramycin alone or could be due to effects apparent only when
fosfomycin and tobramycin were combined in F:T. For example,
altered expression of the fosfomycin targetmurA, the gene encod-
ing the fosfomycin uptake protein (glpT), or genes involved in
tobramycin uptake under anaerobic conditions may be responsi-
ble for the increased activity of F:T. Therefore, the aim of this
study was to characterize the transcriptional response of P. aerugi-
nosa to fosfomycin, tobramycin alone, or F:T, to elucidate the
molecularmechanisms underpinning the increased activity of F:T
under anaerobic conditions.
MATERIALS AND METHODS
Bacterial isolates. The following P. aeruginosa isolates were used in this
study: PAO1 and its narG-C11::ISlacZ/hah, narH-B04::ISphoA/hah,
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phnB-H01::ISlacZ/hah, zwf-B12::ISlacZ/hah, glpT-G02::ISlacZ/hah, and
murA-B03::ISphoA/hah mutants (University of Washington transposon
mutant library) (13); PA14 and PA14 lasR::Gm (14) (Seattle Children’s
Hospital, Seattle, WA); and CM6, CF31, and AN2 (Adult CF Center,
Belfast, United Kingdom). Clinical P. aeruginosa isolates CM6 and CF31
were cultured from CF sputum when patients were clinically stable, and
AN2 was cultured from a sputum sample collected prior to antibiotic
treatment of an acute infective exacerbation. Isolates were cultured from
chronically colonized patients aged 19 (CF31), 22 (CM6), and 41 (AN2)
years, all of whom had received multiple courses of antibiotics for treat-
ment of pulmonary exacerbations.
Anaerobic conditions. For all experiments investigating anaerobic
growth, anaerobic conditions were achieved using an anaerobic worksta-
tion (Whitley A35 anaerobic workstation; Don Whitley Scientific, Shi-
pley, United Kingdom). The presence of anaerobic conditions was con-
tinually monitored using an anaerobic indicator solution (Don Whitley
Scientific, Shipley, United Kingdom). All media used for anaerobic
growth experiments were preincubated in the anaerobic cabinet for at
least 24 h prior to use, to ensure the elimination of oxygen.
Microarray studies. (i) Antibiotic treatment and sampling.Microar-
ray experiments were conducted in triplicate for the clinical isolate P.
aeruginosa CM6 exposed to subinhibitory concentrations (defined as the
highest concentration that did not affect growth [see Fig. S1 in the sup-
plemental material]) of fosfomycin, tobramycin, and F:T under both aer-
obic and anaerobic conditions (24 arrays in total). CM6 was inoculated
into Mueller-Hinton broth (MHB), incubated overnight at 37°C, and
adjusted to an optical density at 550 nm (OD550) of 0.15 (approximately
1 108 CFU/ml). This culture was diluted 1:50 into 24 flasks, each con-
taining 100 ml MHB plus 1% (100 mM) potassium nitrate (KNO3); cul-
tures were then grown with shaking under either aerobic (n  12 flasks)
or anaerobic (n  12 flasks) conditions until early exponential phase
(OD550 0.4). One milliliter of culture was then withdrawn, and 1 ml of
solution containing the appropriate concentration of antibiotic (fosfomy-
cin, 1 mg/liter; tobramycin, 0.25 mg/liter; F:T, 1.25 mg/liter [fosfomycin,
1mg/liter; tobramycin, 0.25mg/liter], and control)was added in triplicate
under both aerobic and anaerobic conditions. Cultures were incubated
with shaking for a further hour, after which 10ml of culture was removed
and centrifuged for 12 min at 3,220  g at 4°C to harvest cells, before
immediately proceeding with RNA extraction.
(ii) RNA extraction. RNA was isolated using TRIzol reagent (Invit-
rogen, United Kingdom) with subsequent DNase 1 digestion per-
formed using the Turbo DNA-free DNase treatment kit (Ambion,
United Kingdom). RNA cleanup was then performed with the Qiagen
RNeasy kit (Qiagen, United Kingdom). RNA was eluted with 40 l diethyl
pyrocarbonate (DEPC)-water, split into aliquots, and immediately stored at
80°C. Full details of RNA extraction are included in the supplemental ma-
terial.
(iii) Microarray hybridization and analysis. Microarray experi-
ments were carried out using Affymetrix GeneChip P. aeruginosa ge-
nome arrays with hybridization performed by Source Bioscience Inc.
(Berlin, Germany). RNA integrity was initially assessed on the Agilent
Bioanalyzer 2100 system (Agilent Technologies, USA). Hybridization
and processing were carried out according to the Affymetrix GeneChip
Expression Analysis Technical Manual. Data were imported into the
Partek Genomics suite (Partek Incorporated, USA) and normalized
using robust multichip average (RMA). Pairwise comparisons were
performed to identify genes that showed differential expression in
response to fosfomycin, tobramycin, and F:T compared to control
values under anaerobic and aerobic conditions. Analysis of variance
(ANOVA) was used to assess significance, with a P value of 0.05
considered significant. Genes with a differential expression of 1.5-
fold were considered for functional analysis.
(iv) Functional and pathway analysis. Genes showing a 1.5-fold
expression change were classified according to PseudoCAP functional
class using the P. aeruginosa genome database (http://www.pseudomonas
.com/index.jsp). Where a gene had more than one functional class, it was
included in all functional classes for the analysis.
(v) qRT-PCR. Validation of 10 genes with differential expression by
microarray analysis was performed using quantitative PCR (qPCR) using
the same RNA as that used in themicroarray experiments (see Table S2 in
the supplemental material). Reactions were carried out on an Applied
Biosystems 7500 Fast real-time PCR detection system (Life Technologies,
United Kingdom). Data were analyzed using the Applied Biosystems 7500
software suite, with differential expression determined by the compara-
tive threshold cycle (CT)method (CT). Full details of quantitative real-
time PCR (qRT-PCR) are included in the supplemental material.
Nitrate utilization assay.Nitrate utilization was determined for PA14
and derived mutant PA14 lasR::Gm, for PAO1 and derived narG-C11::
ISlacZ/hah, narH-B04::ISphoA/hah, narK1-E08::ISlacZ/hah, and narK2-
H03::ISphoA/hah transposon mutants, and for 3 clinical isolates (CM6,
CF31, and AN2) using a nitrate/nitrite colorimetric assay kit (Cayman
Chemical, USA) according to the manufacturer’s instructions. Isolates
were grown overnight and adjusted to an OD550 of 0.15 (approximately
1108 CFU/ml), and 100 l was added to 10 ml MHB plus 1% KNO3 in
duplicate, with one 10-ml volume incubated under aerobic and one incu-
bated under anaerobic conditions with shaking. After 18 h, total viable
counts were determined by serially diluting the bacterial suspension 10-
fold in quarter-strength Ringer’s solution and plating five 10-l drops of
each dilution onto Mueller-Hinton agar (MHA) plates for enumeration
after 24 h. Bacterial suspensions were then centrifuged at 3,220 g for 10
min. The supernatant was removed and vortexed, and 100 l of super-
natant was diluted 1:2,000 in nitrate assay buffer. Absorbance was then
measured in triplicate at 540 nm and a standard curve used to calculate
the concentration of nitrate in each sample. The concentrations were
normalized to nitrate levels in MHB plus 1% KNO3 which had been
incubated without inoculation. Finally, nitrate concentrations were
normalized by cell density in order to correct for the effect of varying
growth rates. Differences in nitrate utilization under anaerobic versus
aerobic conditions were determined by a two-tailed Student t test us-
ing GraphPad Prism software (version 5.00 for Windows; GraphPad
Software, San Diego, CA, USA). Nitrate utilization was also assessed
for 6 strains (AN2, CM6, PAO1, PA14, PA14 lasR::Gm, and PAO1
narG-C11::ISlacZ/hah) following growth in subinhibitory concentra-
tions of fosfomycin, tobramycin, and F:T under anaerobic conditions.
Significant differences in nitrate utilization by the 6 isolates when
exposed to each antibiotic preparation compared to relevant controls
were determined with the GraphPad Prism software using a two-way
ANOVA, with Bonferroni post hoc tests.
Antibiotic susceptibilities of selected transposonmutants. Suscepti-
bility to fosfomycin, tobramycin, andF:Twasdetermined induplicatebyagar
dilution for PA14 and its derived PA14 lasR::Gm mutant and
for PAO1 and its derived glpT-G02::ISlacZ/hah, narG-C11::ISlacZ/hah,
narH-B04::ISphoA/hah, narK1-E08::ISlacZ/hah, narK2-H03::ISphoA/hah,
murA-B03::ISphoA/hah, zwf-B12::ISlacZ/hah, phnA-D11::ISlacZ/hah, and
phnB-H01::ISlacZ/hah transposon mutants under aerobic and anaerobic
conditions as described previously (12).
Growth of selected transposon mutants. Growth of PA14 and PA14
derived mutant PA14 lasR::Gm and of PAO1 and PAO1 derived narG-
C11::ISlacZ/hah, narH-B04::ISphoA/hah, narK1-E08::ISlacZ/hah, narK2-
H03::ISphoA/hah transposon mutants was determined in the presence
and absence of 1% KNO3 under aerobic and anaerobic conditions. Over-
night cultures were adjusted to an OD550 of 0.15 (approximately 110
8
CFU/ml) inMHB and further diluted 1:10, and 50l was added to a total
volume of 20 mlMHBwith or without 1% KNO3. Bacterial cultures were
then incubated under both aerobic and anaerobic conditions and total
viable counts determined after 0, 1, 2, 4, 6, and 24 h.
Microarray data accessionnumber.TheArrayExpress accessionnum-
ber for themicroarray experiments presented in this study is E-MEXP-3764.
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Transcriptional response ofP. aeruginosa to subinhibitory con-
centrations of fosfomycin, tobramycin, and F:T. The gene ex-
pression of clinicalP. aeruginosa isolate CM6was assessed after 1 h
of treatment with subinhibitory concentrations of fosfomycin, to-
bramycin, and F:T under aerobic and anaerobic conditions (see
Table S3 in the supplementalmaterial). Under aerobic conditions,
there were 48 (12 upregulated and 36 downregulated), 287 (62 up-
regulated and 225 downregulated), and 180 (34 upregulated and
146 downregulated) genes with significant expression changes of
1.5-fold in response to growth in subinhibitory fosfomycin, to-
bramycin, and F:T, respectively, compared to controls. Under an-
aerobic conditions, there were 131 (39 upregulated and 92 down-
regulated), 227 (32 upregulated and 195 downregulated), and 81
(33 upregulated and 48 downregulated) genes with significant ex-
pression changes of1.5-fold in response to subinhibitory fosfo-
mycin, tobramycin, and F:T, respectively. In general, the patterns
of altered gene expression as assessed by functional class distribu-
tion for both fosfomycin (Fig. 1a and 2a) and F:T (Fig. 1c and 2c)
were different under aerobic compared with anaerobic condi-
tions. In contrast, the pattern of altered gene expression for tobra-
mycin was similar under aerobic and anaerobic conditions (Fig.
1b and 2b). Furthermore, there were 1,039 genes (531 upregulated
and 508 downregulated) with 1.5-fold expression changes in re-
sponse to growth under anaerobic compared to aerobic conditions
(see Table S3 and Fig. S2 in the supplemental material).
F:T downregulates nitrate reductase genes essential for the
growthofP. aeruginosaunder anaerobic conditions.Thenitrate
reductase gene narG was downregulated most (2.74-fold) by F:T
under anaerobic conditions, with another nitrate reductase gene,
narH (1.67-fold), also downregulated in comparison to the con-
trol (Table 1). The nar genes, which normally are essential for
anaerobic growth of P. aeruginosa (5), did not show altered ex-
pression when exposed to either fosfomycin or tobramycin alone
under either aerobic or anaerobic conditions. Furthermore, other
genes in the nar operon did not show altered expression under any
of the experimental conditions, except for narK1 (3.57-fold) and
narK2 (2.54-fold), encoding nitrate extrusion proteins, which
were significantly downregulated under anaerobic comparedwith
aerobic conditions.
The genemurA, which encodes the fosfomycin target enzyme,
was downregulated by both tobramycin (1.90-fold) and F:T (1.63-
fold) under aerobic conditions. Furthermore, this gene was also
upregulated (1.92-fold) under anaerobic compared to aerobic
conditions. zwf, encoding glucose-6-phosphate dehydrogenase,
which is potentially involved in fosfomycin uptake, was down-
regulated by fosfomycin (1.25-fold), tobramycin (1.73-fold), and
F:T (1.70-fold) under aerobic conditions and also by F:T under
anaerobic conditions (1.44-fold).
Genes potentially involved in tobramycin uptake, phnA (1.82-
fold) and phnB (1.55-fold), were upregulated in response to F:T
under anaerobic conditions. In contrast, phnBwas downregulated
in response to both tobramycin (1.66-fold) and F:T (1.44-fold)
under aerobic conditions. Fosfomycin alone did not affect the
expression of these genes under either condition.
Microarray validation.The results ofmicroarray validation by
FIG 1 PseudoCAP functional class distribution of genes with significantly increased expression (P 0.05) in response to fosfomycin (a), tobramycin (b), and
F:T (c) compared to control values under aerobic (gray bars) and anaerobic (black bars) conditions (excluding genes classified as hypothetical) as identified by
microarray analysis. LPS, lipopolysaccharide.
McCaughey et al.
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qRT-PCR are shown in Fig. S3 to S5 in the supplemental material.
Notably, the qRT-PCR results validated the downregulation of
nitrate reductase genes narG and narH under anaerobic condi-
tions in response to F:T, as found in microarray experiments.
P. aeruginosa nitrate utilization is increased under anaero-
bic conditions. As microarray analysis indicated downregulation
of nitrate reductase genes as a possible mechanism for the in-
creased activity of F:T under anaerobic conditions, the nitrate uti-
lization of PA14, PA14 lasR::Gm, PAO1, PAO1 derived narG-
C11::ISlacZ/hah, narH-B04::ISphoA/hah, narK1-E08::ISlacZ/hah,
and narK2-H03::ISphoA/hah transposon mutants, and 3 clinical
isolates (CM6, CF31, and AN2) were determined under both aer-
obic and anaerobic conditions (Fig. 3). The narG-C11::ISlacZ/hah
and narH-B04::ISphoA/hah nitrate reductase transposonmutants
did not utilize any nitrate under either aerobic or anaerobic con-
ditions. In contrast, the narK1-E08::ISlacZ/hah (P 0.0064) and
FIG 2 PseudoCAP functional class distribution of genes with significantly decreased expression (P 0.05) in response to fosfomycin (a), tobramycin (b), and
F:T (c) compared to control values under aerobic (gray bars) and anaerobic (black bars) conditions (excluding genes classified as hypothetical) as identified by
microarray analysis.
TABLE 1 Fold expression change in selected genes that were significantly differentially expressed (P 0.05) in response to subinhibitory
concentrations of fosfomycin, tobramycin, and F:T compared to control values under aerobic and anaerobic conditions as identified by microarray
analysisa
Category Gene PseudoCAP class Function
Fold expression change








narG Energy metabolism Nitrate reductase 2.74
narH Energy metabolism Nitrate reductase 1.67
narK1 Membrane/transport Nitrate extrusion 3.57
narK2 Membrane/transport Nitrate extrusion 2.54
Fosfomycin
target/uptake
murA Cell wall/LPS/capsule Cell wall synthesis 1.90 1.63 1.92
zwf Energy/carbon compound G6P dehydrogenase 1.25 1.73 1.70 1.44 2.17
glpT Membrane/transport G3P transporter
Tobramycin target/
uptake
phnA Adaption/protection Electron transport chain 1.82 2.71
phnB Adaption/protection Electron transport chain 1.66 1.44 1.55 1.99
hcnA Central intermediary Hydrogen cyanide synthase 1.80 1.68 1.72 1.63
a The full lists of significantly differentially expressed genes can be found in Table S2 in the supplemental material.
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narK2-H03::ISphoA/hah (P  0.0016) nitrate extrusion trans-
poson mutants and isolates PA14, CF31, and AN2 (all P 0.001)
all utilized significantly greater proportions of nitrate under an-
aerobic than under aerobic conditions.
P. aeruginosa nitrate utilization is decreased by subinhibi-
tory concentrations of F:T under anaerobic conditions.We also
measured nitrate utilization for some of the strains shown in Fig. 3
under anaerobic conditions in the absence and presence of subin-
hibitory concentrations of fosfomycin, tobramycin, and F:T, as
shown in Fig. 4. Both antibiotic treatment and strain had a signif-
icant effect on nitrate utilization. There was also a significant in-
teraction between treatment and isolate (P  0.001), indicating
that the effect of treatment was dependent on the isolate tested.
Bonferroni post hoc tests showed that growth in subinhibitory
concentrations of F:T under anaerobic conditions significantly
decreased (P  0.001) nitrate utilization by strains AN2, CM6,
PAO1, PA14, and PA14 lasR::Gm compared to the control, with
no difference apparent for the narG-C11::ISlacZ/hahmutant (Fig.
4). Growth in subinhibitory tobramycin resulted in a significant
decrease (P 0.001) in nitrate utilization for strains AN2, CM6,
and PAO1 (P 0.001) and a significant increase (P 0.001) for
the narG-C11::ISlacZ/hahmutant (P 0.001), with no difference
apparent for PA14 and PA14 lasR::Gm.Nitrate utilization by these
6 strains grown in subinhibitory concentrations of F:T and tobra-
mycin was also measured, demonstrating that nitrate utilization
by PA14, PA14 lasR::Gm, and the narG-C11::ISlacZ/hah mutant
significantly decreased (P 0.001) when grown in subinhibitory
F:T, with no difference apparent for the other 3 strains.
Nitrate reductase transposon mutants have increased sus-
ceptibility to F:T under anaerobic compared to aerobic condi-
tions. The narG-C11::ISlacZ/hah, narH-B04::ISphoA/hah, narK1-
E08::ISlacZ/hah, and narK2-H03::ISphoA/hah mutants each had
2-fold-lower F:T MICs than the parent strain PAO1 under anaer-
obic conditions and also had 2-fold-lower F:TMICs under anaer-
obic than under aerobic conditions (results identical for two in-
dependent experiments) (Table 2). All other PAO1 transposon
FIG 3 Average nitrate utilization ( standard deviation [SD]; n  3) of P. aeruginosa isolates grown in MHB plus 1% KNO3 under aerobic and anaerobic
conditions. Significant differences in nitrate utilization are denoted by asterisks (***, P 0.001; **, P 0.01; *, P 0.05).
FIG 4 Average nitrate utilization (SD; n 3) by P. aeruginosa isolates when
exposed to subinhibitory concentrations of fosfomycin (Fof), tobramycin
(Tob), or F:T or to control treatment (no antibiotic added) under anaerobic
conditions. Significant differences in nitrate utilization when exposed to fos-
fomycin, tobramycin, and F:T compared to control values and for F:T com-
pared to tobramycin are denoted by asterisks (***, P 0.001; **, P 0.01; *,
P  0.05). F:T significantly decreased the nitrate utilization of all isolates
tested, including a lasRmutant isolate known to exhibit increased nitrate uti-
lization.
McCaughey et al.
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mutants had 2-fold-lower F:T MICs than wild-type PAO1 under
both aerobic and anaerobic conditions.
Nitrate reductase transposonmutants are at a growth disad-
vantage under anaerobic conditions. Under aerobic conditions,
all PAO1 transposonmutants showed growth rates similar to that
of the PAO1wild-type strainwhen grown in either the presence or
absence of nitrate (see Fig. S6 in the supplemental material). Un-
der anaerobic conditions, the PAO1 narG-C11::ISlacZ/hah, narH-
B04::ISphoA/hah, narK1-E08::ISlacZ/hah, and narK2-H03::IS-
phoA/hah nitrate reductase transposon mutants were at a growth
disadvantage compared to wild-type PAO1 when grown in the
absence of 1% KNO3 (Fig. 5). Similarly, when these 4 strains were
grown under anaerobic conditions in the presence of 1% KNO3,
all were still at a growth disadvantage compared to wild-type
PAO1. This growth disadvantage was relatively less pronounced
for the narK2-H03::ISphoA/hahmutant. PA14 and PA14 lasR::Gm
demonstrated similar growth under anaerobic conditions in both
the absence and presence of nitrate.
DISCUSSION
Previous work has showed that F:T, a 4:1 combination of fosfo-
mycin and tobramycin for treatment of CF respiratory infection,
has enhanced activity under anaerobic conditions (12). In this
study, we used DNA microarrays to analyze the transcriptional
response of a clinical P. aeruginosa isolate (CM6) to subinhibitory
F:T, fosfomycin, and tobramycin under both aerobic and anaero-
bic conditions. The results of microarray studies were confirmed
by laboratory-based experiments using both clinical P. aeruginosa
isolates and transposon mutants of laboratory strains of PAO1
and PA14, as the clinical isolate employed in themicroarray study
wasmultidrug resistant and not suitable for geneticmanipulation.
Our results show that F:T elicited a transcriptional response
distinct from that of either of its constituents alone under both
aerobic and anaerobic conditions. Importantly, we report that
F:T, but not fosfomycin or tobramycin alone, can downregulate
the expression of membrane-bound nitrate reductase genes narG
and narH under anaerobic conditions. This was confirmed by
nitrate utilization assays, which demonstrated that subinhibitory
concentrations of F:T significantly reduced nitrate utilization in P.
aeruginosa. Previously, it has been shown that narG and narH are
required for anaerobic growth of P. aeruginosa, with knockout
mutants unable to grow under these conditions (4). Furthermore,
a narG mutant had a severe growth defect under anaerobic con-
ditions in media containing nitrate at concentrations found in CF
TABLE 2 Fosfomycin, tobramycin, and F:T MICs of P. aeruginosa transposon mutants and clinical strains under aerobic and anaerobic conditions
Strain




Aerobic conditions Anaerobic conditions
Fosfomycin Tobramycin F:T Fosfomycin Tobramycin F:T
PAO1 32 1 10 16 8 10
PAO1 narG-C11::ISlacZ/hah 32 1 10 16 2 5 2
PAO1 narH-B04::ISphoA/hah 32 1 10 16 4 5 2
PAO1 narK1-E08::ISlacZ/hah 32 1 10 16 4 5 2
PAO1 narK2-H03::ISphoA/hah 32 1 10 16 4 5 2
PAO1 phnA-D11::ISlacZ/hah 32 1 5 16 4 5
PAO1 phnB-H01::ISlacZ/hah 64 1 5 16 4 5
PAO1 zwf-B12::ISlacZ/hah 64 1 5 512 4 5
PAO1 glpT-G02::ISlacZ/hah ,2048 1 5 2,048 4 5
PAO1murA-B03::ISphoA/hah 32 1 5 64 2 5
PA14 16 1 2.5 4 8 10 4
PA14 lasR::Gm 32 2 10 16 8 10
CM6a 16 128 40 32 8 10 4
CF31a 4 32 20 16 32 10 2
AN2a 4 64 20 16 16 10 2
a Susceptibility data taken from previously published data (12).
b Negative values indicate a reduction in MIC under anaerobic conditions, and positive values indicate an increase in MIC under anaerobic conditions. Nitrate reductase
transposon mutants had 2-fold-lower F:T MICs under anaerobic than under aerobic conditions.
FIG 5 Growth of nitrate reductase transposonmutants inMHB under anaer-
obic conditions without KNO3 (A) and with 1% KNO3 added to the growth
medium (B). Nitrate reductase transposon mutants had a growth defect com-
pared to the parent PAO1 strain in both the presence and absence of KNO3.
Fosfomycin:Tobramycin under Anaerobic Conditions
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sputum (4, 5). These results are consistent with the findings of the
current study, which found that narG, narH, narK1, and narK2
transposon mutants had significant growth defects compared
with their parent strain under anaerobic conditions. We also
showed that narG and narH transposon mutants were unable to
reduce nitrate under either condition. While the nar transposon
mutants are unable to reduce nitrate, it is possible that their lim-
ited growth under anaerobic conditions is supported by other
pathways involved in anaerobic growth, such as the nitric oxide
reductase (nor) and the periplasmic nitrate reductase (nap) path-
ways (15, 16). In addition, pyruvate fermentation may contribute
to the survival of these strains under anaerobic conditions (17).
The nitrate reductase transposon mutants had a 2-fold reduction
in F:T MIC under anaerobic compared to aerobic conditions, in
agreement with results of a previous study using clinical P. aerugi-
nosa isolates with F:T (12). Therefore, it is highly likely that the
effect of F:T on the expression of nitrate reductase genes explains
the increased activity of F:T against P. aeruginosa under anaerobic
conditions.
Given the importance of nitrate reduction to the anaerobic
growth of P. aeruginosa in the CF lung, the ability of F:T to reverse
nitrate utilization by P. aeruginosa isolates, including a lasR mu-
tant known to exhibit increased nitrate utilization, was investi-
gated. lasRmutants are associated with poor prognostic outcome
in CF, have increased antimicrobial resistance, and have a growth
advantage in the nitrate-rich CF lung (14, 18, 19). Furthermore,
there is selective pressure in favor of nitrate utilization in the CF
lung, suggesting that mutations that increase the ability of P.
aeruginosa to respire nitrate confer a selective advantage in this
environment (20, 21). F:T significantly reduced nitrate utilization
in P. aeruginosa isolates, including the lasR mutant. Tobramycin
alone also significantly reduced nitrate utilization in some of the
strains; however, importantly, it was unable to reverse nitrate uti-
lization by the lasRmutant.
This is the first report of an antimicrobial combination reduc-
ing the expression of nitrate reductase genes and reducing the
ability of P. aeruginosa to respire using nitrate, a feature essential
for normal anaerobic growth. This finding could be of clinical
importance, as reversal of nitrate utilization may affect the ability
of P. aeruginosa to chronically colonize the nitrate-rich CF lung
and may reverse the selective advantage of lasR strains in this
environment. Our results also suggest that nitrate utilization is
tractable and may potentially be manipulated in the CF lung. The
nar operon is conserved in a broad range of bacteria (22) and also
allows for hypoxic or anaerobic respiration in clinically relevant
pathogens, including Escherichia coli,Mycobacterium tuberculosis,
and Moraxella catarrhalis (23–26). Furthermore, it has recently
been shown that nitrate generated as a by-product of the host
inflammatory response conferred a fitness advantage to E. coli in
the gut (27). It is possible that a similarmechanism could generate
nitrate in the CF lung, where excessive inflammation is present.
This, together with the link between increased nitrate utilization
and antimicrobial resistance, suggests nitrate metabolism and the
nar operon as attractive targets for the development of antimicro-
bial adjuvants for use in chronic infections.
P. aeruginosa uses nitrate as an alternative terminal electron
acceptor during anaerobic respiration and can also perform aero-
bic denitrification (28–31). In the present study, a significant dif-
ference in the expression of themajority of nitrate reductase genes
under anaerobic as opposed to aerobic conditions was not found.
While this finding was surprising, other studies have reported
similar results. For example, Wagner et al. found that narK1 and
narK2, nitrate extrusion protein genes, were downregulated under
anaerobic conditions (32). Similarly, Filiatrault et al. (33) found
that genes subsequently identified as essential for growth under
anaerobic conditions were downregulated under anaerobic con-
ditions (15). In contrast, Platt et al. reported that genes involved
in nitrate reduction are upregulated under anaerobic com-
pared to aerobic conditions (34). Interestingly, CM6 utilized
similar amounts of nitrate under both aerobic and anaerobic
conditions, correlating with the similar expression levels of the
nar genes under both conditions found in this study. It is also
likely that many of these genes are constitutively expressed
under both aerobic and anaerobic conditions, with low-level
expression of the nap operon independent of oxygen tension
having been previously observed (4).
We also hypothesized that differential expression of the fosfo-
mycin target murA may have been responsible for the increased
activity of fosfomycin and F:T under anaerobic conditions.murA
encodes an enzyme involved in peptidoglycan synthesis and was
downregulated by both tobramycin and F:T under aerobic condi-
tions. Overexpression of this gene has previously been shown to
confer fosfomycin resistance in E. coli (35). Interestingly, the
murA transposon mutant had a 4-fold-higher fosfomycin MIC
under anaerobic conditions but had lower F:TMICs than the wild
type under aerobic and anaerobic conditions. The decreased sus-
ceptibility of themurA transposon mutant to fosfomycin is prob-
ably due to lack of a fosfomycin target, supporting a previous
study that identified amino acid substitutions in murA that con-
ferred fosfomycin resistance (36). Interestingly, Petek et al. did not
find that fosfomycin caused significant differential expression of
murA, in agreement with the current results (37). In addition,
murAwas upregulated under anaerobic compared to aerobic con-
ditions, negating the possibility that decreased expression of the
fosfomycin target under anaerobic conditions is responsible for
the enhanced activity of fosfomycin or F:T.
Recently, it has been shown that the glycerol-3-phosphate
transporter, GlpT, is the only transporter for fosfomycin in P.
aeruginosa (38) and that fosfomycin is not taken up by a glucose-
6-phosphate-induced transporter as in E. coli (39). Therefore, it
was possible that the increased activity of fosfomycin and F:T un-
der anaerobic conditions was due to an upregulation of GlpT;
however, our results indicate that this transporter is not differen-
tially regulated under anaerobic conditions. Thus, increased ac-
tivity of fosfomycin under anaerobic conditions is unlikely to be as
a result of increased expression of GlpT in P. aeruginosa.
The decreased activity of aminoglycosides under anaerobic
conditions is frequently attributed to reduced uptake under these
conditions (6–8). Macleod et al. used radiolabeled tobramycin to
show that tobramycin uptake was energy dependent and was en-
hanced by fosfomycin under aerobic conditions (40). Therefore,
we postulated that the increased activity of F:T may be due to
fosfomycin-mediated increased uptake of tobramycin under an-
aerobic conditions. Previously, MacLeod et al. suggested a possi-
ble partial role in tobramycin uptake for the outer membrane
porin OprB (40). However, in the current study, expression of the
oprB gene was similar under all conditions tested and was not
upregulated in the presence of fosfomycin or F:T. Two genes in-
volved in the electron transport chain and in ubiquinone biosyn-
thesis, both of which are required for aminoglycoside uptake (41),
McCaughey et al.
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phnA and phnB, were upregulated in response to growth under
anaerobic conditions; however, phnA and phnB transposon mu-
tants did not have increased tobramycin MICs, and it is therefore
unlikely that these genes encode products that are crucial for to-
bramycin uptake.
Both tobramycin and F:T were found to downregulate expres-
sion of the glucose-6-phosphate dehydrogenase gene, zwf, under
aerobic conditions; F:T also downregulated this gene under anaer-
obic conditions. Previously, it has been shown thatmutations that
upregulate expression of this gene confer resistance to oxidative
stress and paraquat (42, 43). Conversely, it would be expected that
downregulation of this gene would increase susceptibility to oxi-
dative stress, a potentially important effect, as aminoglycosides
such as tobramycin are believed to exert their action at least in part
by producing reactive oxygen species (44, 45). However, the zwf
transposon mutant did not exhibit increased susceptibility to to-
bramycin under aerobic conditions. Interestingly, the zwf trans-
poson mutant had an increased fosfomycin MIC under aerobic
conditions, and the mutation conferred resistance under anaero-
bic conditions. This indicates that zwf has an as-yet-uncharacter-
ized role in fosfomycin resistance.
In summary, this study showed that F:T downregulates the
expression of nitrate reductase genes that are essential for the
growth of P. aeruginosa under anaerobic conditions. This effect
may explain the increased activity of F:T under anaerobic condi-
tions. Expression of these genes was unchanged in response to F:T
under aerobic conditions or in response to either fosfomycin or
tobramycin alone. F:T also reduced nitrate utilization in CF P.
aeruginosa isolates and in a lasRmutant strain, which is known to
have increased nitrate utilization compared to that by the wild
type. Therefore, F:T may be a particularly promising treatment
option in patients chronically colonized with lasR-deficient iso-
lates, which are associated with poorer clinical prognosis.
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